Literature DB >> 11525649

Differences in patterns of activation of MAP kinases induced by oncogenic ras-p21 and insulin in oocytes.

M Ranginwale1, S Smith, J Flom, L Chie, M Kanovsky, D Chung, F K Friedman, R C Robinson, P W Brandt-Rauf, Z Yamaizumi, J Michl, M R Pincus.   

Abstract

Oncogenic ras (Val 12-containing)-p21 protein induces oocyte maturation by a pathway that is blocked by peptides from effector domains of ras-p21, i.e., residues 35-47 (that block Val 12-p21-activated raf) and 96-110 and 115-126, which do not affect the ability of insulin-activated cellular p21 to induce maturation. Oncogenic p21 binds directly to jun-N-terminal kinase (JNK), which is blocked by the p21 96-110 and 115-126 peptides. This finding predicts that oncogenic p21, but not insulin, induces maturation by early and sustained activation of JNK. We now directly confirm this prediction by showing that oncogenic p21 induces activating phosphorylation of JNK (JNK-P) and of ERK (MAP kinase) (MAPK-P), whose levels correlate with oocyte maturation. p21 peptides 35-47 and 96-110 block formation of JNK-P and MAPK-P, further confirming this correlation and suggesting, unexpectedly, that raf-MEK-MAPK and JNK-jun pathways strongly interact on the oncogenic p21 pathway. In contrast, insulin activates only low levels of JNK-P, and, surprisingly, we find that insulin induces only low levels of MAPK-P, indicating that insulin and activated normal p21 utilize MAP kinase-independent signal transduction pathways. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11525649     DOI: 10.1006/excr.2001.5311

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  3 in total

1.  Loop domain peptides from the SOS ras-guanine nucleotide exchange protein, identified from molecular dynamics calculations, strongly inhibit ras signaling.

Authors:  Lyndon Chie; Fred K Friedman; Thomas Duncan; James M Chen; Denise Chung; Matthew Pincus
Journal:  Protein J       Date:  2004-04       Impact factor: 2.371

2.  Novel peptides from the RAS-p21 and p53 proteins for the treatment of cancer.

Authors:  Wilbur B Bowne; Josef Michl; Martin H Bluth; Michael E Zenilman; Matthew R Pincus
Journal:  Cancer Ther       Date:  2007

3.  An effector peptide from glutathione-S-transferase-pi strongly and selectively blocks mitotic signaling by oncogenic ras-p21.

Authors:  Lyndon Chie; Victor Adler; Fred K Friedman; Denise Chung; Matthew R Pincus
Journal:  Protein J       Date:  2004-04       Impact factor: 2.371

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.